A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

BACKGROUND: Fibroblast growth factors (FGFs) have a fundamental role in cancer. Sequestering FGFs with GSK3052230 (FP-1039) blocks their ability to activate FGFRs while avoiding toxicities associated with small molecule inhibitors of FGFR, including hyperphosphatemia and retinal, nail, and skin toxi...

Full description

Saved in:
Bibliographic Details
Published in:Invest New Drugs
Main Authors: van Brummelen, Emilie M. J., Levchenko, Evgeny, Dómine, Manuel, Fennell, Dean A., Kindler, Hedy L., Viteri, Santiago, Gadgeel, Shirish, López, Pilar Garrido, Kostorov, Vladimir, Morgensztern, Daniel, Orlov, Sergey, Zauderer, Marjorie G., Vansteenkiste, Johan F., Baker-Neblett, Katherine, Vasquez, James, Wang, Xiaowei, Bellovin, David I., Schellens, Jan H. M., Yan, Li, Mitrica, Ionel, DeYoung, M. Phillip, Trigo, José
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6898757/
https://ncbi.nlm.nih.gov/pubmed/31065954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00783-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items